GFR tyrosine kinases inhibitors in cancer treatment: In vitro and in vivo evidence

Anna Elisa Quatrale, Letizia Porcelli, Nicola Silvestris, Giuseppe Colucci, Angelo Paradiso, Amalia Azzariti

Research output: Contribution to journalArticlepeer-review


The increasing understanding of the molecular mechanisms of neoplastic transformation and progression has prompted the search for novel drugs that could interfere with the intracellular targets involved in this process. EGFR is implicated in the development and progression of the majority of the common human epithelial cancer; therefore different agents have been developed to block EGFR activation in cancer cells. This review focuses on EGFR-tyrosine kinase inhibitors in clinical practice that interfere with ATP binding, inhibiting tyrosine kinase activity and subsequently blocking signal transduction from EGFR. We report current knowledge on molecular mechanisms underlying the anticancer activity of EGFR-tyrosine kinase inhibitors in preclinical models, with particular attention to EGFR downstream effectors responsible for treatment efficacy or resistance.

Original languageEnglish
Pages (from-to)1962-1972
Number of pages11
JournalFrontiers in Bioscience
Issue number5
Publication statusPublished - Jan 1 2011


  • Biological activity
  • Cancer treatment
  • EGFR tyrosine kinase inhibitors
  • Erlotinib
  • Gefitinib
  • Lapatinib
  • Mechanisms of action
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)


Dive into the research topics of 'GFR tyrosine kinases inhibitors in cancer treatment: In vitro and in vivo evidence'. Together they form a unique fingerprint.

Cite this